title: [Thalidomide: (re)discovery of a not very dear old molecule].
abstract: The angiogenesis is an early event in tumorigenesis. Angiogenesis inhibitors have been developed and are now studied in clinical trials. Angiogenesis research has induced a renewal of thalidomide. Thalidomide inhibits tumoral angiogenesis, allowing a good palliative treatment for hematological malignancies, especially for multiple myeloma and myelodysplastic syndromes.
authors.affiliation: Service d'Oncologie Hôpital des Cadolles, 2000 Neuchâtel. alberic.bressoud@ne.ch
authors.forename: Albéric
authors.initials: A
authors.lastname: Bressoud
authors.forename: Béatrice Zimmerli
authors.initials: BZ
authors.lastname: Schwab
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide